GSK’s Anoro Ellipta Heads To FDA Panel With Higher Hopes For Higher Dose
This article was originally published in The Pink Sheet Daily
Executive Summary
The lead LAMA/LABA combination for COPD will be reviewed at the Sept. 10 session of the Pulmonary-Allergy Drugs Advisory Committee.